Abstract
VEXAS syndrome, an autoinflammatory syndrome due to a Ubiquitin Like Modifier Activating Enzyme 1 (UBA1) somatic mutation, has a high thrombotic burden. We report a case of a 69-year-old male that was diagnosed with VEXAS syndrome who developed venous thromboembolism (VTE). Review of literature of existing VEXAS syndrome cases showed a high thrombotic burden, with the reported incidence of VTE (36.4%) being markedly higher than arterial thrombosis (1.6%), with deep vein thrombosis being more common than pulmonary embolism. Somatic mutation in the UBA1 gene results in decreased ubiquitylation which is a key driver in the development of thrombosis in VEXAS syndrome, due to chronic inflammation and cytokine release from abnormal crosstalk between the intrinsic effector mechanism of innate immune cells, platelets and endothelium resulting in dysregulated haemostasis and endothelial dysfunction. Targeting endothelial dysfunction and reducing inflammatory milieu causing hypercoagulability with immunosuppressants and immunomodulatory agents, together with anticoagulation may be the strategy to prevent recurrent thrombotic events.


Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628–2638. https://doi.org/10.1056/NEJMoa20268342
Fan BE, Cao L, Gallardo CA et al (2021) Myeloid and lymphoid vacuolation in VEXAS syndrome. Am J Hematol 96(8):1056–1057. https://doi.org/10.1002/ajh.26098
Georgin-Lavialle S, Terrier B, Guedon AF et al (2021) Further characterization of clinical and laboratory features occurring in VEXAS syndrome in a large-scale analysis of multicenter case-series of 116 French patients. Br J Dermatol. https://doi.org/10.1111/bjd.20805
Obiorah IE, Patel BA, Groarke EM et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203–3215. https://doi.org/10.1182/bloodadvances.2021004976
van der Made CI, Potjewijd J, Hoogstins A et al (2021) Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.05.014
Bourbon E, Heiblig M, Gerfaud Valentin M et al (2021) Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 137(26):3682–3684. https://doi.org/10.1182/blood.2020010177
Poulter JA, Collins JC, Cargo C et al (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 137(26):3676–3681. https://doi.org/10.1182/blood.2020010286
Tsuchida N, Kunishita Y, Uchiyama Y et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220089
Lacombe V, Prevost M, Bouvier A et al (2021) Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol. https://doi.org/10.1111/bjh.17679
Arlet JB, Terrier B, Kosmider O (2021) Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 384(22):2163. https://doi.org/10.1056/NEJMc2102124
Barba T, Jamilloux Y, Durel CA et al (2021) VEXAS syndrome in a woman. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keab392
Ivanova EA, Orekhov AN (2016) The role of endoplasmic reticulum stress and unfolded protein response in atherosclerosis. Int J Mol Sci. 17(2):193. https://doi.org/10.3390/ijms17020193
Grey A, Cheong PL, Lee FJ et al (2021) A case of VEXAS syndrome complicated by hemophagocytic lymphohistiocytosis. J Clin Immunol 41(7):1648–1651. https://doi.org/10.1007/s10875-021-01070-y
Najem MY, Couturaud F, Lemarié CA (2020) Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost 18(5):1009–1019
McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF (2017) Weibel-Palade bodies at a glance. J Cell Sci 130(21):3611–3617. https://doi.org/10.1242/jcs.208033
Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13(1):34–45. https://doi.org/10.1038/nri3345
Borissoff JI, ten Cate H (2011) From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost 9(9):1791–1794. https://doi.org/10.1111/j.1538-7836.2011.04425.x
Rautou PE, Mackman N (2013) Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol 6(1):91–101. https://doi.org/10.1586/ehm.12.74
Muratore F, Marvisi C, Castrignanò P et al (2021) VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol. https://doi.org/10.1002/art.41992
Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7(6):330–339
Acknowledgements
The authors greatly appreciate the efforts of our fellow healthcare workers during this COVID-19 pandemic.
Funding
No funding was required for this study.
Author information
Authors and Affiliations
Contributions
BEF conceived the study. All authors contributed substantially to the acquisition, analysis and interpretation of data, critical revision of manuscript for important intellectual content.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Written consent was obtained from the patient.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Oo, T.M., Koay, J.T.J., Lee, S.F. et al. Thrombosis in VEXAS syndrome. J Thromb Thrombolysis 53, 965–970 (2022). https://doi.org/10.1007/s11239-021-02608-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-021-02608-y